Suppr超能文献

吸入前列环素治疗肺动脉高压:在新生儿中的氧合指数改善比在大龄儿童中更一致。

Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children.

机构信息

Department of Anesthesiology and Critical Care Medicine, Baltimore, Maryland, USA.

出版信息

Pulm Circ. 2012 Jan-Mar;2(1):61-6. doi: 10.4103/2045-8932.94835.

Abstract

The purpose of this study was to determine the efficacy of inhaled epoprostenol for treatment of acute pulmonary hypertension (PH) in pediatric patients and to formulate a plan for a prospective, randomized study of pulmonary vasodilator therapy in this population. Inhaled epoprostenol is an effective treatment for pediatric PH. A retrospective chart review was conducted of all pediatric patients who received inhaled epoprostenol at a tertiary care hospital between October 2005 and August 2007. The study population was restricted to all patients under 18 years of age who received inhaled epoprostenol for greater than 1 hour and had available data for oxygenation index (OI) calculation. Arterial blood gas values and ventilator settings were collected immediately prior to epoprostenol initiation, and during epoprostenol therapy (as close to 12 hours after initiation as possible). Echocardiograms were reviewed during two time frames: Within 48 hours prior to therapy initiation and within 96 hours after initiation. Of the 20 patients in the study population, 13 were neonates, and the mean OI for these patients improved during epoprostenol administration (mean OI before and during therapy was 25.6±16.3 and 14.5±13.6, respectively, P=0.02). Mean OI for the seven patients greater than 30 days of age was not significantly different during treatment (mean OI before and during therapy was 29.6±15.0 and 25.6±17.8, P=0.56). Improvement in echocardiographic findings (evidence of decreased right-sided pressures or improved right ventricular function) was demonstrated in 20% of all patients. Inhaled epoprostenol is an effective therapy for the treatment of selected pediatric patients with acute PH. Neonates may benefit more consistently from this therapy than older infants and children. A randomized controlled trial is needed to discern the optimal role for inhaled prostanoids in the treatment of acute PH in childhood.

摘要

这项研究的目的是确定吸入依前列醇治疗儿科患者急性肺动脉高压(PH)的疗效,并为该人群的肺血管扩张剂治疗前瞻性、随机研究制定计划。吸入依前列醇是治疗儿科 PH 的有效方法。回顾性分析了 2005 年 10 月至 2007 年 8 月期间在一家三级保健医院接受吸入依前列醇治疗的所有儿科患者的病历。研究人群仅限于所有接受吸入依前列醇治疗超过 1 小时且有计算氧合指数(OI)数据的 18 岁以下患者。在开始依前列醇治疗前和治疗期间(尽可能接近开始后 12 小时)收集动脉血气值和呼吸机设置。在两个时间段回顾心脏超声:在治疗开始前 48 小时内和开始后 96 小时内。在研究人群中的 20 名患者中,有 13 名是新生儿,这些患者的 OI 在依前列醇治疗期间有所改善(治疗前和治疗期间的平均 OI 分别为 25.6±16.3 和 14.5±13.6,P=0.02)。大于 30 天的 7 名患者在治疗期间的 OI 没有明显差异(治疗前和治疗期间的平均 OI 分别为 29.6±15.0 和 25.6±17.8,P=0.56)。所有患者中有 20%显示超声心动图检查结果改善(右侧压力降低或右心室功能改善的证据)。吸入依前列醇是治疗选定的儿科急性 PH 患者的有效方法。新生儿可能比年龄较大的婴儿和儿童更能持续受益于这种治疗。需要进行随机对照试验以确定吸入前列腺素在儿童急性 PH 治疗中的最佳作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1610/3342750/e3a69c7009ee/PC-2-61-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验